Page 33 - Read Online

Gonzalez Castillo et al. J Transl Genet Genom. 2025;9:338-51 https://dx.doi.org/10.20517/jtgg.2025.57 Page 348

Writing, editing and supervision: Batley K, Iannaccone ST
All authors have reviewed and agreed to the published version of the manuscript.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Iannaccone ST is an Editor and Editorial Board Member of Journal of Translational Genetics and Genomics.
Iannaccone ST was not involved in any steps of editorial processing, notably including reviewers' selection,
manuscript handling and decision making, Iannaccone ST has served as a consultant for Sarepta
Therapeutics, TRINDS, Merck, BioMarin, Broadstreet and Astellas; Gonzalez Castillo Z has served on
advisory boards for ITF Therapeutics and Sarepta Therapeutics; Batley K has received research funding
from Catalyst Pharmaceuticals, Sarepta Therapeutics, and NS Pharma. She has served on advisory boards
and/or as a speaker for Catalyst Pharmaceuticals, ITF Therapeutics, Sarepta Therapeutics, Pfizer, and
Regenxbio; Nelson L declares that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2025.

REFERENCES
1. Sun C, Shen L, Zhang Z, Xie X. Therapeutic strategies for duchenne muscular dystrophy: an update. Genes. 2020;11:837. DOI
PubMed PMC
2. Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: an updated
systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:141. DOI PubMed PMC
3. Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochmüller H. Life expectancy at birth in Duchenne muscular
dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35:643-53. DOI PubMed PMC
4. Armstrong N, Apkon S, Berggren KN, et al. The early care (0-3 Years) in duchenne muscular dystrophy meeting report. J
Neuromuscul Dis. 2024;11:525-33. DOI
5. Sarker S, Eshaque TB, Soorajkumar A, et al. Mutational spectrum and phenotypic variability of Duchenne muscular dystrophy and
related disorders in a Bangladeshi population. Sci Rep. 2023;13:21547. DOI PubMed PMC
6. Selvatici R, Rossi R, Fortunato F, et al. Ethnicity-related DMD genotype landscapes in European and non-European countries. Neurol
Genet. 2021;7:e536. DOI
7. Amr K, Fahmy N, El-Kamah G. Genomic insights into Duchene muscular dystrophy: analysis of 1250 patients reveals 30% novel
genetic patterns and 6 novel variants. J Genet Eng Biotechnol. 2024;22:100436. DOI PubMed PMC
8. Zinina E, Bulakh M, Chukhrova A, et al. Specificities of the DMD gene mutation spectrum in Russian patients. Int J Mol Sci.
2022;23:12710. DOI PubMed PMC
9. Neri M, Rossi R, Trabanelli C, et al. The genetic landscape of dystrophin mutations in Italy: a nationwide study. Front Genet.
2020;11:131. DOI PubMed PMC
10. Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular
dystrophy mutations. Hum Mutat. 2015;36:395-402. DOI
11. Esposito G, Tremolaterra MR, Marsocci E, et al. Precise mapping of 17 deletion breakpoints within the central hotspot deletion region
(introns 50 and 51) of the DMD gene. J Hum Genet. 2017;62:1057-63. DOI
12. Oshima J, Magner DB, Lee JA, et al. Regional genomic instability predisposes to complex dystrophin gene rearrangements. Hum
Genet. 2009;126:411-23. DOI